Oxford Science Enterprises (OSE) is an Oxford-based venture capital firm founded in 2015 and dedicated specifically to commercialising world-class research from the University of Oxford. It focuses on Pre-Seed, Seed, and Series A investments in spin-outs across Life Sciences, Health Tech, and Deep Tech. Compared with broader venture firms, OSE stands out for its unique, long-term partnership with the University, providing it with a privileged "first look" and founding rights to the institution’s most promising intellectual property.
‍
Its investment interests span biotechnology, quantum computing, nuclear fusion, and digital health diagnostics. The firm’s thesis is rooted in the convergence of academic excellence and global commercial impact, targeting "boundary-pushing" science that addresses major global challenges. This makes it especially relevant to founders emerging from the Oxford ecosystem who require deep technical expertise, specialized lab infrastructure, and patient capital to navigate long development cycles.
‍
OSE is primarily UK-focused, centered on the "Golden Triangle" of Oxford, Cambridge, and London, but it maintains a global network of co-investors to scale its companies internationally. For science-based founders, it is the most critical specialist fund to track in the UK because its mandate is explicitly tied to the Oxford research pipeline rather than general market deal flow. It is most relevant for early-stage academic entrepreneurs seeking a founding partner that deeply understands the complexities of spinning out high-science ventures.